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Blocking Von Willebrand Factor for Treatment of
Cutaneous Inflammation
Carina Hillgruber1,2, Annika K. Steingra¨ber1, Birgit Po¨ppelmann1, Ce´cile V. Denis3, Jerry Ware4,
Dietmar Vestweber5, Bernhard Nieswandt6, Stefan W. Schneider7 and Tobias Goerge1,2
Von Willebrand factor (VWF), a key player in hemostasis, is increasingly recognized as a proinflammatory protein.
Here, we found a massive accumulation of VWF in skin biopsies of patients suffering from immune complex
(IC)–mediated vasculitis (ICV). To clarify the impact of VWF on cutaneous inflammation, we induced experimental
ICV either in mice treated with VWF-blocking antibodies or in VWF / mice. Interference with VWF led to a
significant inhibition of the cutaneous inflammatory response. We confirmed the major findings in irritative
contact dermatitis, a second model of cutaneous inflammation. In vivo imaging of cutaneous inflammation in the
dorsal skinfold chamber revealed unaffected leukocyte rolling on anti-VWF treatment. However, we identified
that reduced leukocyte recruitment is accompanied by reduced vascular permeability. Although VWF-mediated
neutrophil recruitment to the peritoneum was described to require the VWF receptor on platelets (glycoprotein
Iba (GPIba)), the VWF/GPIba axis was dispensable for cutaneous inflammation. As assessed in tail bleeding
assays, we could exclude interference of VWF blockade with hemostasis. Of particular importance, anti-VWF
treatment was effective both in prophylactic and therapeutic administration. Thus, VWF represents a promising
target for the treatment of cutaneous inflammation, e.g., leukocytoclastic vasculitis.
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INTRODUCTION
Immune complex (IC)–mediated vasculitis (ICV) is a charac-
teristic hallmark of a range of human autoimmune diseases
such as rheumatoid arthritis, systemic lupus erythematosus,
glomerulonephritis, or leukocytoclastic vasculitis (LcV) (Tsuboi
et al., 2008; Mayadas et al., 2009). LcV, the most common
type of vasculitis in dermatology, is defined by inflammation
of the vascular wall, mainly of postcapillary venules (Jennette
et al., 2012). The vasculitic process is initiated by formation of
antigen–antibody complexes and their precipitation at the
vessel wall (Lotti et al., 1998). IC deposition subsequently
leads to activation and recruitment of neutrophils that foster
the inflammatory response by release of proteinases, elastases,
and free oxygen radicals (Claudy, 1998; Lamprecht and Gross,
2011). The regulation of leukocyte recruitment to the inflam-
matory sites through endothelial interaction via selectins and
integrins is well known (Ley et al., 2007). However, additional
cofactors contributing to leukocyte recruitment were identi-
fied; e.g., a supporting role of platelets was shown (Carvalho-
Tavares et al., 2000; Vowinkel et al., 2007).
Recently, von Willebrand factor (VWF) was described to be
a major regulator of leukocyte extravasation during experi-
mental peritonitis (Petri et al., 2010). VWF is a multimeric
hemostatic protein that is released by both endothelial cells
and platelets (Wagner, 1990; Sadler, 1998). Beside its role for
platelet adhesion during hemostasis, VWF has become a
relevant target in studies of the inflammatory response
(Denis et al., 2001; Khan et al., 2012; Shen et al., 2012).
Animal studies have shown that deficiency of VWF provides
protection against ischemic stroke (Kleinschnitz et al., 2009)
and atherosclerosis (Methia et al., 2001; van Galen et al.,
2012).
In the circulation, VWF multimers are strictly controlled by
ADAMTS-13 (a disintegrin and metalloproteinase with throm-
bospondin type I motif-13) that constitutively cleaves ultra-
large VWF strings into smaller, less adhesive multimers (Levy
et al., 2001; Chung and Fujikawa, 2002; Dong et al., 2002;
Turner et al., 2009), thus preventing thrombotic
thrombocytopenic purpura (Levy et al., 2001; Motto et al.,
2005; Chauhan et al., 2008). Animal studies have shown that
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ADAMTS-13 has protective effects against ischemic brain
damage and reduces VWF-mediated acute cerebral inflam-
mation following stroke (Zhao et al., 2009; Fujioka et al.,
2010).
Others have investigated VWF antagonists such as the
aptamers ARC1779 or ARC15105 (Firbas et al., 2010;
Siller-Matula et al., 2012) and a VWF recognizing nanobody
(Callewaert et al., 2012), thus indicating that targeting VWF
becomes increasingly interesting for therapy of vascular
diseases. But while these studies of blocking VWF aimed at
developing new antithrombotics, less is known about the anti-
inflammatory properties of targeting VWF. In particular,
concerning IC-mediated inflammation, there is desperate
need for a targeted treatment more specific than standard
immunosuppressive therapy.
Therefore, this study investigates the impact of VWF on
cutaneous inflammation. Interestingly, cutaneous vasculitis
results in robust VWF accumulation in human tissue. As a
consequence, we subjected VWF / mice or mice treated
with anti-VWF antibodies to the reverse passive Arthus
reaction, the prototypic mouse model for ICV (Zax et al.,
1990; Kaburagi et al., 2002; Goerge et al., 2008) and revealed
significantly reduced inflammation. These findings were also
confirmed in irritative contact dermatitis (ICD). Our results
demonstrate that VWF plays a regulatory role in cutaneous
inflammation. As the treatment with anti-VWF antibodies
significantly counteracts ICV and does not cause enhanced
bleeding times, our findings reveal that targeting VWF is
beneficial for the effective treatment of ongoing cutaneous
inflammation.
RESULTS AND DISCUSSION
VWF accumulation during cutaneous inflammation
The IC-mediated inflammation such as LcV is characterized by
leukocyte infiltration and edema formation in the inflamed
tissue. Recently, VWF was shown to be a major regulator of
leukocyte recruitment during experimental peritonitis (Petri
et al., 2010). However, the role of VWF during cutaneous
inflammation is completely unknown. In a first step to clarify a
putative involvement of VWF in cutaneous inflammatory
processes, the presence of VWF protein in inflamed human
and murine skin was studied. Therefore, skin biopsies of
patients suffering from LcV (n¼10) were histologically analy-
zed and compared with healthy skin controls. In addition, we
studied skin biopsies of mice that were subjected to murine
models of ICV and ICD. Hematoxylin and eosin staining of
skin biopsies showed inflammatory infiltrates and edema
formation in both human LcV and murine ICV (Figure 1a
and b). Interestingly, immunofluorescent staining revealed
robust VWF accumulation in the inflamed tissue whereas in
healthy skin controls VWF was only found in endothelial cells
as shown by colocalized positive staining for the endothelial
marker CD31 (Figure 1c–e). The discovery of accumulated
VWF in the inflamed tissue raises the question of its origin. In
general, VWF is found in platelets and endothelial cells, and
pathways of constitutive and regulated release are described
(Giblin et al., 2008; Wang et al., 2011; Luo et al., 2012).
Here, the accumulated VWF in inflamed human tissue is most
likely due to endothelial secretion. Previous studies described
phorbol 12-myristate 13-acetate, the active component of
croton oil, as a potent inducer of VWF release from endo-
thelial cells (Kim et al., 2010; Valentijn et al., 2010).
Moreover, stimulation of human umbilical vein endothelial
cells with preformed anti-BSA/BSA ICs caused VWF release as
well (Supplementary Figure S1 online), thus identifying ICs as
potent VWF secretagogues in human umbilical vein endothe-
lial cells. In summary, we observe a robust VWF accumulation
in inflamed human and murine skin.
VWF mediates cutaneous inflammation
Previous work in the mouse peritoneum and cremaster
described strong inhibitory effects on neutrophil extravasation
through functional blocking of VWF (Petri et al., 2010). To
investigate the impact of VWF on cutaneous inflammation, a
well-characterized polyclonal antibody (Tan and Ginsburg,
2008) (against human VWF and highly crossreactive with
murine VWF) was used to block VWF function in murine
models of ICV and ICD. Control IgG or anti-VWF antibodies
were injected intravenously followed by induction of ICV or
ICD combined with administration of Evans Blue dye, a
marker for vascular permeability. At 4 hours after inflamma-
tory stimulation, the decrease of Evans Blue intensity in anti-
VWF-treated animals indicated reduced tissue leakage as
compared with control IgG-treated mice (Figure 2a and d).
As shown in Figure 2b and e, VWF blockade significantly
reduced leukocyte recruitment during both ICV and ICD, as
measured by the leukocyte marker myeloperoxidase (MPO;
ICV: control IgG 21.8±1.1 vs. anti-VWF 12.2±0.9; ICD:
control IgG 4.0±0.4 vs. anti-VWF 1.8±0.3 n-fold to control
skin). Moreover, the analysis of biopsy wet weights showed
a significant decrease of edema formation in the anti-VWF-
treated group (ICV: control IgG 2.2±0.1 vs. anti-VWF 1.4±
0.03; ICD: control IgG 1.9±0.1 vs. anti-VWF 1.5±0.04
n-fold to control skin). The reduction of neutrophil recruitment
to the inflamed skin through anti-VWF antibodies was a dose-
dependent effect and was also efficient in blocking severe
inflammation (Supplementary Figure S2 online). Reduced
numbers of infiltrated leukocytes on anti-VWF treatment could
be confirmed by hematoxylin and eosin staining (Figure 2c
and f). The predominant leukocytes in the present inflamma-
tory models are neutrophils—an impact of VWF on regulation
of T-cell extravasation should be studied in appropriate
models. Our findings thus demonstrate a regulatory role of
VWF for the innate cutaneous inflammatory response.
VWF / mice are protected from cutaneous inflammation
As VWF appears to play a general role for leukocyte recruit-
ment to the skin, we questioned whether the effect of block-
ing antibodies could be confirmed in VWF-deficient mice
(VWF / ). To this end, VWF / mice were subjected to the
ICV (Figure 3a) as well as the ICD (Figure 3b) model.
Representative images show reduced Evans Blue tissue leak-
age at the inflammatory sites of VWF / mice. Of note,
at the sites of anti-BSA injection, hemorrhage is observed in
VWF / mice because of their genetic bleeding disorder.
Cutaneous inflammation as measured by MPO activity (ICV:
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47.4±3.9%; ICD 67.0±7.8% reduction in VWF / ) and
biopsy wet weight (ICV: 46.8±8.7%; ICD 62.2±9.9% reduc-
tion in VWF / ) was markedly reduced in VWF / animals
as compared with wild-type (WT) mice (Figure 3c and d).
Thus, both anti-VWF antibody treatment and deficiency of
VWF result in a significant reduction of the inflammatory
response in the skin. Concerning our findings in VWF /
mice, it has to be kept in mind that VWF / mice are difficult
to study as their genetic modification also leads to a storage
defect of endothelial Weibel–Palade bodies, thus causing a
defect in regulated secretion of P-selectin. In detail, in
mesenteric venules of histamine-treated VWF / mice,
P-selectin expression has been shown to be virtually absent
(Denis et al., 2001). Therefore, we predominantly used the
polyclonal anti-VWF antibodies for our studies as their
specificity has been proven in previous work (Petri et al.,
2010). This well-characterized antibody binds to epitopes in
the D’D3 region that was shown to mediate VWF/leukocyte
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Figure 1. Cutaneous inflammation leads to von Willebrand factor (VWF) accumulation in human and murine skin. (a) Representative photograph of a patient
suffering from leukocytoclastic vasculitis (LcV), and hematoxylin and eosin (H&E) staining of inflamed skin presenting inflammatory infiltrates (black arrows) and
red blood cell extravasation (red arrows). Bar¼ 100mm. (b) Representative murine back skin with Evans Blue leakage at the three sites of immune complex–
mediated vasculitis (ICV) induction (dotted circles). H&E staining of an inflammatory spot reveals massive recruitment of inflammatory cells (black arrows).
Bar¼100mm. Representative images of (c) human and (d, e) murine skin biopsies immunofluorescently stained for VWF (green) and CD31 (red). Ctrl, control; ICD,
irritative contact dermatitis. Bar¼ 50mm. Quantification results of VWF/CD31 ratio are presented in scatter dot plots of nX6 per group. **Po0.01 and
***Po0.001.
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interaction and does not block the glycoprotein Iba
(GPIba)–binding site in the A1 region (Pendu et al., 2006;
Tan and Ginsburg, 2008). It is thus an excellent tool for
studying VWF function in inflammation independent of
GPIba-mediated hemostasis.
VWF promotes cutaneous leukocyte recruitment and vascular
permeability
To understand the VWF-mediated mechanism leading to
leukocyte extravasation in the skin, we further investigated
the effects of VWF blockade by intravital microscopy. Pre-
viously, we reported that the dorsal skinfold chamber (DSC) is
a powerful tool for continuous visualization of inflammatory
leukocyte recruitment in the dermal microcirculation (Goerge
et al., 2008; Feld et al., 2012). For visualization of cell
recruitment and vessel wall interactions, mice were
transfused with calcein green–labeled bone marrow cells from
WT donors. Skin inflammation was induced by application of
1% croton oil on the backside of the DSC. As we could show
here, in vivo imaging in the DSC confirmed our findings of a
significantly reduced neutrophil recruitment on VWF blockade
during cutaneous inflammation. At 90 minutes after ICD
challenge, microscopic examination revealed a decreased
amount of recruited cells into the inflamed tissue of mice
treated with anti-VWF antibodies as compared with controls
(Figure 4a and b and Supplementary Video S1 online). Having
a closer look at early steps of cutaneous leukocyte extravasa-
tion, we observed by video stream analysis that the amount of
rolling cells was unaffected through anti-VWF treatment
(Figure 4c). This is in line with previous work showing that
leukocyte rolling depends on P-selectin glycoprotein ligand-1
(PSGL-1) binding to the VWF A1 domain that is not blocked
by the applied antibody (Pendu et al., 2006; Tan and
Ginsburg, 2008). As VWF supports leukocyte recruitment
but does not influence leukocyte rolling, we hypothesized
that VWF-dependent neutrophil recruitment might be
mediated by an effect downstream of cutaneous neutro-
phil adhesion and rolling. As VWF does not only promote
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Figure 2. The von Willebrand factor (VWF)-blocking antibodies reduce cutaneous inflammatory response. (a) Immune complex–mediated vasculitis (ICV) is
induced in three spots of the back skin (dotted circles), whereas (d) irritative contact dermatitis (ICD) induction causes one homogenous spot as visualized by Evans
Blue tissue leakage. (b, e) Impact of anti-VWF antibodies on myeloperoxidase (MPO) activity (left charts) and edema formation (right charts) during ICV and ICD is
shown. Data are presented as mean values±SEM of relative increase to healthy control skin (n¼ 8–12 mice per group; ***Po0.001). (c, f) Hematoxylin and eosin
(H&E) staining of biopsies from the sites of inflammation permits analysis of recruited leukocytes (arrows) in the skin of anti-VWF-treated mice versus control (ctrl)
animals. Bar¼ 50mm.
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leukocyte recruitment but also edema formation (Figures 2 and
3), we investigated a role of VWF for endothelial permeability.
By intradermal injection of the vasoactive agonists histamine
and vascular endothelial growth factor, we observed a sig-
nificant reduction of vascular permeability on VWF blockade
(Figure 4d). This finding indicates that VWF might contribute to
cutaneous leukocyte recruitment via regulation of endothelial
permeability. However, the mechanism whereby VWF regu-
lates even leukocyte-independent endothelial permeability still
needs to be clarified in more detail. It can be speculated that
VWF interaction with endothelial avb3 integrin might regulate
endothelial permeability via outside-in signaling (Huang et al.,
2009). This hypothesis is supported by data that VWF binds to
avb3 integrin via its RGD motif located outside the A1 domain
(Denis et al., 1993), which is required for leukocyte rolling
(Pendu et al., 2006).
Platelet GPIba/VWF interaction is not required for leukocyte
recruitment to the skin
In a next set of experiments we asked whether the interaction
of VWF with GPIba, its ligand on platelets, might be
responsible for leukocyte recruitment to the inflamed skin.
Others have reported a contribution of the VWF receptor
(GPIba) to tumor cell extravasation during lung metastasis and
to neutrophil recruitment during peritonitis (Jain et al., 2007;
Petri et al., 2010). Interestingly, in contrast to observations
from the peritoneum, the GPIba/VWF axis is not required for
leukocyte recruitment to the skin (Supplementary Figure S3
online). Our observations underline the fact that the mechan-
isms leading to neutrophil recruitment are heterogeneous and
critically depend on the inflamed tissue (Mizgerd et al., 1997).
Data obtained from inflamed peritoneum, lung, or cremaster
are not necessarily transferable to skin pathology (Rossaint and
Zarbock, 2012). It may be discussed whether the skin as a
barrier organ relies on a less restrictive regulation of leukocyte
infiltration to secure a more rapid response to acute
inflammation.
Blocking antibodies against VWF do not affect bleeding time
VWF becomes more and more interesting as a medical target
as there are first preclinical and clinical studies investigat-
ing, e.g., VWF blockade by aptamer (Firbas et al., 2010;
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Jilma-Stohlawetz et al., 2012; Siller-Matula et al., 2012) or
nanobody (Callewaert et al., 2012) administration. Moreover,
the VWF-cleaving protease ADAMTS-13 provides protection
from thrombotic thrombocytopenic purpura (Chauhan et al.,
2008) and brain injury in experimental stroke (De Meyer et al.,
2012; Khan et al., 2012), thus fostering the rising interest in
VWF as a therapeutic target. For dermatologists it is of interest
in how far blocking VWF might be therapeutically useful
during cutaneous inflammation. Therefore, we studied
putative effects of anti-VWF antibodies on hemostasis. We
subjected anti-VWF-treated mice to a tail bleeding assay and
observed that VWF-blocking antibodies do not cause
prolonged bleeding times whereas VWF / mice have a
bleeding disorder (Figure 5a) (Marx et al., 2008; Zhao et al.,
2009). This result is supported by our observation (1) that
VWF-mediated neutrophil recruitment does not depend on
hemostatic GPIba (Supplementary Figure S3a–c online),
(2) that anti-VWF treatment does not target the VWF/GPIba
axis (Supplementary Figure S3d online) and (3) is in line with
previously published data that the used anti-VWF antibody
does not block the GPIba-binding site in the A1 region (Tan
and Ginsburg, 2008). As a control, mice lacking GPIba
(GPIba/IL4R-tg mice) or treated with GPIba-Fab’ fragments
showed prolonged bleeding times as expected (Figure 5a)
(Ware et al., 2000; Bergmeier et al., 2006). These findings
are of particular interest as they open up the possibility to
inhibit inflammation without interfering with the VWF/GPIba-
mediated hemostasis.
Therapeutic administration of anti-VWF antibodies reduces
ongoing cutaneous inflammation
As administration of anti-VWF antibodies antagonizes
cutaneous inflammation but does not interfere with GPIba-
mediated hemostasis, we hypothesized that anti-VWF
treatment could be used to interfere with the cause of
ongoing cutaneous inflammation. Therefore, mice were
injected with anti-VWF antibodies or control IgG 2 hours after
ICV induction. After 4 hours, mice were analyzed (Figure 5b).
Evans Blue leakage revealed a decreased inflammatory
response on therapeutic anti-VWF treatment (Figure 5c).
Moreover, leukocyte recruitment (control IgG 9.9±0.5 vs.
anti-VWF 5.5±0.4 n-fold to control skin) and tissue edema
(control IgG 1.4±0.05 vs. anti-VWF 1.1±0.03 n-fold to
control skin) were significantly reduced (Figure 5d). By
analyzing the thickness in the ICD ear model for 24 hours,
we observed that both anti-VWF antibodies and genetic VWF
deficiency protect from edema formation (Figure 5e and f).
What is more, treatment of advanced inflammation leads to
immediate regression of the inflammatory response (Figure 5e).
Thus, our results show the therapeutic effectiveness of
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anti-VWF treatment for the reduction of ongoing cutaneous
inflammation.
In this study, we found a relevant role for VWF in IC-
mediated inflammation in humans and confirmed our obser-
vations in animal studies. VWF considerably contributes to
cutaneous neutrophil recruitment—most likely in association
with vascular permeability—thus representing a promising
anti-inflammatory target. Anti-VWF treatment successfully
blocks cutaneous inflammation without affecting bleeding
time. In conclusion, our presented findings convey targeting
VWF as an innovative approach for specific therapy of
ongoing cutaneous inflammation.
MATERIALS AND METHODS
Animals
C57BL/6J (WT) mice, 6 to 10 weeks old, were purchased from Harlan
Laboratories (Venray, The Netherlands) and kept under specific
pathogen-free (SPF) conditions. Transgenic mice lacking GPIba
(GPIba/IL4Ra-tg, background: C57BL/6J) (Ware et al., 2000; Kanaji
et al., 2002) were bred and housed in our specific pathogen-free
animal facility. Mice deficient in VWF (VWF / , background:
C57BL/6J) (Denis et al., 1998) were bred at the Max Planck
Institute for Molecular Biomedicine (Mu¨nster, Germany). All
experimental animal procedures have been approved by the local
authorities (District Government and District Veterinary Office,
Mu¨nster, Germany).
Antibodies
The following antibodies were used: polyclonal rabbit antibody
against human VWF and crossreactive with murine VWF (dialyzed
against endotoxin-free phosphate-buffered saline (PBS); A0082, Dako,
Glostrup, Denmark) (Tan and Ginsburg, 2008), normal rabbit IgG
control antibody (dialyzed against endotoxin-free PBS; Invitrogen,
Darmstadt, Germany), mouse anti-human CD31 (clone WM59,
BioLegend, Fell, Germany), rat anti-mouse CD31 (clone MEC13.3,
BD Pharmingen, Heidelberg, Germany), nondepleting blocking
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formation on anti-VWF therapy. (e) ICD-induced ear swelling on interference with VWF, measured at indicated time points. Results are presented as mean
values±SEM of nX4 mice per group. *Po0.05; **Po0.01; ***Po0.001. Ctrl, control; GPIba, glycoprotein Iba; NS, not significant; WT, wild type.
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anti-GPIba Fab’ fragment (p0p/B, Emfret, Eibelstadt, Germany), and
rabbit anti-BSA (B7276, Sigma-Aldrich, Taufkirchen, Germany).
Reagents
Croton oil, Evans Blue, MPO from human leukocytes, tetramethyl-
benzidine, and histamine were purchased from Sigma-Aldrich. BSA
was obtained from PAA (Pasching, Austria). Recombinant murine
vascular endothelial growth factor was used from PeproTech (Hamburg,
Germany). Hexadecyltrimethyl-ammonium bromide was from
Acros Organics (Geel, Belgium). DABCO and Mowiol 4-88 were
purchased from Roth (Karlsruhe, Germany). DAPI (40,6-diamidino-2-
phenylindole dihydrochloride) was obtained from Roche Diagnostics
(Mannheim, Germany). Mounting medium Vectashield was from
Vector Laboratories (Biozol, Eching, Germany). Hematoxylin 2 and
Eosin-Y were from Thermo Scientific (St Leon-Rot, Germany).
Tail bleeding assay
Using a sharp scalpel, 3 mm of the distal tail tip of mice was cut. The
tail was immediately immersed in 37 1C prewarmed water and the
time until stable cessation of blood flow for 15 seconds was deter-
mined as bleeding time. In case of continuous bleeding, experiments
were terminated after 5 minutes.
Immune complex–mediated vasculitis
ICV was induced by intravenous injection of BSA (150ml, 1% in PBS
per 20 g mouse) immediately followed by intradermal injection of
anti-BSA antibody (20ml, 1:5 in PBS) under anesthesia by isoflurane
inhalation (Forene 100%, Abbott, Ludwigshafen, Germany). For
visualization of vascular leakage Evans Blue (50ml, 1% in PBS per
20 g mouse) was administered with the BSA injection. Mice were
killed after 4 hours and skins were harvested. Punch biopsies of 8 mm
diameter were taken, weighed, homogenized, and analyzed for MPO
activity or analyzed histologically. Before ICV induction, WT mice
were treated with anti-VWF antibodies (100mg in PBS, retro-orbital)
or normal rabbit IgG. For therapeutic approaches mice received anti-
VWF antibodies or control IgG 2 hours after ICV induction.
Irritative contact dermatitis
Croton oil in acetone (10ml) was applied topically to the shaved
dorsal skin (1%) or to one ear (5%) of mice. Olive oil in acetone
served as a control. At 4 hours after ICD induction at the back skin,
skins were harvested and analyzed as described above. Ear swelling
was measured hourly for 6 hours and at 24 hours.
Determination of MPO activity
Analysis of MPO activity was performed as described previously
(Bradley et al., 1982). Briefly, skin biopsies were shred in PBS, centri-
fuged (13,000 r.p.m. for 10 minutes at room temperature), and resus-
pended in hexadecyltrimethyl-ammonium bromide lysis buffer (1% in
50 mM potassium phosphate buffer). After centrifugation (13,000 r.p.m.
for 10 minutes at room temperature), the supernatant was assessed in
triplicates for MPO activity by adding tetramethylbenzidine substrate.
Absorbance was measured at 630 nm for 20 minutes in a microplate
reader (BioTek, Bad Friedrichshall, Germany).
In vivo imaging in the DSC
WT mice were anesthetized by intraperitoneal injection of ketamine
(80 mg kg 1; Ceva, Du¨sseldorf, Germany) and xylazine (14 mg kg 1;
Ceva), and surgical preparation of DSC was performed as we have
described previously (Goerge et al., 2008; Feld et al., 2012). Mice
were allowed to recover from surgery for 24 hours. For in vivo
microscopic observations, skinfold chamber preparation was attached
to the microscope stage and intravital microscopy was performed on
an epifluorescence microscope (AxioImager Z.2; Zeiss, Jena, Germany)
using  2.5 and  10 magnification objectives. Before intravital
microscopy was performed, 3 107 bone marrow cells, extracted
from WT donor mice, were labeled with calcein green (5mg ml 1;
Invitrogen) and intravenously injected into recipient mice. Subseq-
uently, mice were treated with 100mg anti-VWF antibodies or control
IgG and ICD was performed in the DSC. Leukocyte recruitment was
recorded by attached cameras (AxioCam MRm/AxioCam MRc; Zeiss)
and data acquisition was performed with AxioVision software
(version 4.8; Zeiss). For quantification of recruited bone marrow
cells, cells were counted and the amount was normalized to the
corresponding vessel area (vessel diameter length; mm2). Leukocyte
rolling was analyzed in postcapillary venules (inner vessel diameter
30–50mm) and quantified offline for 15 seconds in video streams.
Rolling leukocytes were defined as cells moving slower than the
corresponding local blood stream.
Permeability assay in the skin
Mice received an intradermal injection of either histamine (20ml,
100mM in PBS) or vascular endothelial growth factor (20ml, 100 ng in
PBS). PBS served as control. After 30 minutes skins were harvested.
Punch biopsies of 8 mm diameter were taken, weighed, and stored in
formamide for 24 hours. Evans blue intensity in supernatants was
measured photometrically at 630 nm.
Histological analysis
Human and murine punch biopsies were either fixed in formalin for
paraffin embedding or in OCT matrix (NEG 50, Thermo Scientific) for
cryostat sectioning. Paraffin-embedded specimens were stained with
hematoxylin and eosin, and frozen specimens were stained for VWF
(anti-VWF; FITC-labeled secondary antibody) and endothelial cells
(anti-CD31; Alexa Fluor 568–labeled secondary antibody, Life Tech-
nologies, Frankfurt, Germany). Samples stained with hematoxylin and
eosin were mounted with Vectashield and examined on an AxioOb-
server Z.1 (Axioplan, Zeiss). Immunofluorescent samples were counter-
stained with DAPI, mounted with DABCO–Mowiol and analyzed with
an AxioImager Z.2 (Axioplan, Zeiss). For quantification of VWF/CD31
ratio, the red and green channels of equally exposed digital photographs
of the samples were subjected to the histogram function of photoshop
(Adobe Photoshop CS5, Adobe Systems, Mu¨nchen, Germany).
Statistical analysis
Data are presented as mean±SEM. Statistical evaluation and plotting
was done in SigmaPlot (Version 11.0, Systat Software, Erkrath,
Germany) or GraphPad Prism (GraphPad Software, La Jolla, CA).
When comparing two groups, Student’s t-test or Mann–Whitney rank-
sum test was performed. One-way analysis of variance or Kruskal–
Wallis analysis of variance on ranks was used if two or more groups
were analyzed. Values of *Po0.05, **Po0.01, and ***Po0.001
were regarded as statistically significant.
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